Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6187438 | PMC |
| http://dx.doi.org/10.1177/0706743718773708 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
'My Advocacy is Not About Me, My Advocacy is About Canadians': A Qualitative Study of how Caregivers and Patients Influence Regulation of Medical Assistance in Dying in Canada.
Med Law Rev
August 2024
Faculty of Business and Law, School of Law, Australian Centre for Health Law Research, Queensland University of Technology, Brisbane, Australia.
Medical assistance in dying (MAiD) was legalised federally in Canada after the Supreme Court decision in Carter v Canada (Attorney General) [2015] 1 SCR 331. The federal legislative framework for MAiD was established via Bill C-14 in 2016. Caregivers and patients were central to Carter and subsequent litigation and advocacy, which resulted in amendments to the law via Bill C-7 in 2021.
View Article and Find Full Text PDFPractitioners' experiences with 2021 amendments to Canada's medical assistance in dying law: a qualitative analysis.
Palliat Care Soc Pract
December 2023
Australian Centre for Health Law Research, Faculty of Business and Law, Queensland University of Technology, Brisbane, QLD, Australia.
Background: In 2016, Canada joined the growing number of jurisdictions to legalize medical assistance in dying (MAiD), when the Supreme Court of Canada's decision in took effect and the Canadian Parliament passed Bill C-14. Five years later, Bill C-7 introduced several significant amendments. These included removing the 'reasonably foreseeable natural death' requirement (an aspect that was widely debated) and introducing the final consent waiver.
View Article and Find Full Text PDFAssessing Boron-Pleuromutilin AN11251 for the Development of Antibacterial Agents.
Molecules
June 2023
Department of DMPK & Tox, Global Health Drug Discovery Institute, Zhongguancun Dongsheng International Science Park, Beijing 100192, China.
Pleuromutilins are a group of antibiotics derived from the naturally occurring compound. The recent approval of lefamulin for both intravenous and oral doses in humans to treat community-acquired bacterial pneumonia has prompted investigations in modifying the structure to broaden the antibacterial spectrum, enhance the activity, and improve the pharmacokinetic properties. AN11251 is a C(14)-functionalized pleuromutilin with a boron-containing heterocycle substructure.
View Article and Find Full Text PDFMAiD as a case study in evidence for policy making: An account of the CCA assessment on medical assistance in dying.
Healthc Manage Forum
May 2023
Council of Canadian Academies, Ottawa, Ontario, Canada.
In December 2016, the Council of Canadian Academies (CCA) was asked by the Government of Canada to undertake an assessment on Medical Assistance in Dying (MAiD), following from Parliament's passage of Bill C-14: . The CCA was asked to undertake an assessment of the state of knowledge on three topics that Parliament excluded from C-14: requests for MAiD by mature minors, advance requests for MAiD, and requests for MAiD where a mental disorder is the sole underlying medical condition. Here, we describe the way that the CCA responded to the request from the Government of Canada using a multidisciplinary expert panel approach, how different forms of evidence were identified and used, the impact of the CCA assessment as part of the broader conversation occurring in Canada, and its implications for health leaders.
View Article and Find Full Text PDFExperiences of healthcare providers with eligible patients' loss of decision-making capacity while awaiting medical assistance in dying.
Palliat Care Soc Pract
October 2022
Trillium Health Partners-Mississauga Hospital, Mississauga, ON, CanadaLawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, ON, CanadaJoint Centre for Bioethics, University of Toronto, Toronto, ON, Canada.
Background: In Canada, under Bill C-14, patients who met all eligibility requirements were prevented from accessing medical assistance in dying (MAiD) following their loss of decision-making capacity while awaiting MAiD. The changes introduced with Bill C-7 continue to limit access to patients who did not enter a waiver of final consent agreement with their healthcare providers. Little is known about the experiences with patients' loss of capacity to consent and subsequent ineligibility for MAiD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!